FY2027 Earnings Estimate for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Leerink Partnrs increased their FY2027 earnings per share estimates for shares of Avadel Pharmaceuticals in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $1.50 for the year, up from their previous estimate of $1.40. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals' FY2028 earnings at $2.15 EPS.

Several other research firms also recently issued reports on AVDL. Oppenheimer lifted their price target on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. HC Wainwright reiterated a "buy" rating and set a $21.00 price objective (down from $25.00) on shares of Avadel Pharmaceuticals in a report on Friday, January 10th. Needham & Company LLC lowered their target price on shares of Avadel Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating on the stock in a report on Thursday, January 9th. Piper Sandler cut their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Finally, UBS Group lowered their price objective on Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $21.00.

Avadel Pharmaceuticals Price Performance

Shares of AVDL traded up $0.21 during trading hours on Friday, hitting $8.18. The stock had a trading volume of 786,857 shares, compared to its average volume of 1,721,282. The firm has a market capitalization of $787.74 million, a P/E ratio of -10.35 and a beta of 1.28. Avadel Pharmaceuticals has a 1-year low of $7.39 and a 1-year high of $19.09. The firm has a 50 day simple moving average of $9.63 and a 200-day simple moving average of $12.64.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The firm had revenue of $50.00 million for the quarter, compared to analyst estimates of $48.43 million. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. The company's revenue was up 624.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.41) earnings per share.

Insiders Place Their Bets

In other news, Director Linda Palczuk bought 3,000 shares of the firm's stock in a transaction on Friday, December 6th. The stock was acquired at an average cost of $10.19 per share, with a total value of $30,570.00. Following the completion of the transaction, the director now directly owns 66,400 shares of the company's stock, valued at $676,616. This represents a 4.73 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Thomas S. Mchugh purchased 5,000 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average cost of $10.49 per share, for a total transaction of $52,450.00. Following the transaction, the chief financial officer now directly owns 85,500 shares in the company, valued at approximately $896,895. The trade was a 6.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 55,579 shares of company stock valued at $526,363 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVDL. Braidwell LP boosted its holdings in Avadel Pharmaceuticals by 16.9% in the 3rd quarter. Braidwell LP now owns 3,388,939 shares of the company's stock worth $44,446,000 after buying an additional 490,300 shares during the period. State Street Corp increased its holdings in Avadel Pharmaceuticals by 42.5% during the 3rd quarter. State Street Corp now owns 1,623,302 shares of the company's stock worth $21,290,000 after acquiring an additional 483,787 shares during the period. Barclays PLC lifted its stake in Avadel Pharmaceuticals by 45.8% in the 3rd quarter. Barclays PLC now owns 392,691 shares of the company's stock worth $5,150,000 after purchasing an additional 123,430 shares in the last quarter. Wealth Effects LLC grew its position in shares of Avadel Pharmaceuticals by 4.9% during the 4th quarter. Wealth Effects LLC now owns 2,344,130 shares of the company's stock valued at $24,637,000 after purchasing an additional 110,359 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its holdings in shares of Avadel Pharmaceuticals by 23.9% in the third quarter. Lord Abbett & CO. LLC now owns 489,073 shares of the company's stock worth $6,414,000 after purchasing an additional 94,239 shares during the period. 69.19% of the stock is currently owned by institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.